KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:KPTI

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/03/07	06 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/03/05	06 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/03/05	06 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/03/05	06 : 51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/03/05	06 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/03/05	06 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/03/04	06 : 05	PR Newswire (US)	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/25	06 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/24	22 : 40	PR Newswire (US)	Karyopharm Announces 1-for-15 Reverse Stock Split	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/20	06 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/19	21 : 32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/19	21 : 30	PR Newswire (US)	Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/12	23 : 36	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/12	21 : 00	PR Newswire (US)	Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/06	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/04	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/04	06 : 05	PR Newswire (US)	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/02/01	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/01/31	06 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/01/13	22 : 34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/01/13	22 : 30	PR Newswire (US)	Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/01/08	06 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/01/07	07 : 07	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/01/03	06 : 05	PR Newswire (US)	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/01/02	21 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2025/01/02	21 : 00	PR Newswire (US)	Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2024/12/17	06 : 00	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2024/12/09	22 : 00	PR Newswire (US)	Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2024/12/06	06 : 35	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:KPTI	Karyopharm Therapeutics Inc
2024/12/06	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KPTI	Karyopharm Therapeutics Inc